• Explore /
  • Poster
  • / Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.

Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.

Abstract Video & Slides Poster

Authors

Elisa Rozeman

Elisa A. Rozeman

Netherlands Cancer Institute, Amsterdam, Netherlands

Elisa A. Rozeman , Irene L.M. Reijers , Esmée P Hoefsmit , Karolina Sikorska , Oscar Krijgsman , Bart A. Van De Wiel , Petros Dimitriadis , Hanna Eriksson , Maria Gonzalez , Lindsay G Grijpink-Ongering , Ron M. Kerkhoven , Annegien Broeks , Willem M.C. Klop , Andrew Spillane , Robyn PM Saw , Alexander Christopher Jonathan Van Akkooi , Richard A. Scolyer , Alexander M. Menzies , Georgina V. Long , Christian U. Blank

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT02977052

Citation

J Clin Oncol 38: 2020 (suppl; abstr 10015)

DOI

10.1200/JCO.2020.38.15_suppl.10015

Abstract #

10015

Poster Bd #

364

Abstract Disclosures

Similar Posters

First Author: Irene L.M. Reijers

First Author: Judith M. Versluis

First Author: Irene L.M. Reijers

First Author: Milton Jose De Barros E Silva